Generate Biomedicines, Inc.
NASDAQ:GENBAsset Management
+$0.13 today
- Market cap
- $1.34B
- Beta
- 0.19
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$4.06
Volume 1.05M
Average 0.55M
GENB Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Generate Biomedicines, Inc.NASDAQ: GENB
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation of $0 in Q1 FY2026
Q1 FY2026 stock-based compensation was $0.
Context
- Stock-based compensation amounted to 64.5% of revenue in FY2025, down 30.6 pp from a year earlier.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 20.58M USD
- Year-over-year change
- +5.7%
- 1-year CAGR
- +5.7%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.58M | +5.7% |
| FY2024 | 2024-12-31 | 19.47M | — |
Stock-Based Compensation vs competitors
How GENB compares with its peers on the latest reported figures
- GENB's FY2025 stock-based compensation of $20.58M is the 2nd largest of the 5 companies compared; the peer median is $12.44M.
- Its year-over-year change of +5.7% is the highest of 5, against a peer median of -37.2%.
- Stock-based compensation amounts to 64.5% of revenue for GENB, versus a peer median of 404.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $48.87M | -15.9% | +4.1% | 72.0% | |
GENBGenerate Biomedicines, Inc. | FY2025 | $20.58M | +5.7% | — | 64.5% |
| LTM Mar 2026 | $13.53M | -11.4% | +13.5% | 737.0% | |
| LTM Mar 2026 | $11.34M | -79.7% | -18.3% | 872.4% | |
| LTM Mar 2026 | $10.03M | -58.5% | -18.9% | 10.1% | |
| Peer median (excluding GENB) | $12.44M | -37.2% | -7.1% | 404.5% | |
Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (181.38M) | (222.97M) |
| Depreciation & Amortization | 15.35M | 13.18M |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 19.47M | 20.58M |
| Change in Working Capital | 28.12M | (14.62M) |
| Accounts Receivables | (213K) | 308K |
| Inventory | 0 | 0 |
| Accounts Payables | 3.5M | (2.13M) |
| Other Working Capital | 24.83M | (12.79M) |
| Other Non-Cash Items | 702K | 3.21M |
| Operating Cash Flow | (117.75M) | (200.62M) |
| Capital Expenditures | (3.45M) | (3.51M) |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | (282.98M) | (164.73M) |
| Sales of Investments | 228.69M | 285.01M |
| Other Investing Activities | 10K | 0 |
| Investing Cash Flow | (57.73M) | 116.77M |
| Debt Repayment | (11.12M) | (8.16M) |
| Common Stock Issued | 0 | 0 |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 6.13M | 14.25M |
| Financing Cash Flow | 91.33M | 28.06M |
| Effect of Forex Changes | 0 | 0 |
| Net Change in Cash | (84.15M) | (55.79M) |
| Free Cash Flow | (121.2M) | (204.13M) |
Generate Biomedicines, Inc.
NASDAQ:GENB
Intrinsic Alpha fair value
Locked
Current Price
$10.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.